preliminary information has suggested that megestrol acetate leads to appetite stimulation and nonfluid weight gain in patients with breast cancer other cancers and aidspursuant to this we developed a randomized doubleblind placebocontrolled trial of megestrol acetate in patients with cancerassociated anorexia and cachexiawe randomly assigned 133 eligible patients to receive 800 mg of megestrol acetate per day or a placebopatients assigned to megestrol acetate more frequently reported improved appetite p  003 and food intake p  009 when compared with patients receiving the placeboa weight gain of 15 lb or more over baseline was seen in 11 of 67 16 patients receiving megestrol acetate compared with one of 66 2 given the placebo p  003patients receiving megestrol acetate reported significantly less nausea 13 vs 38 p  001 and emesis 8 vs 25 p  009no clinically or statistically significant toxic reactions were ascribed to megestrol acetate with the exception of mild edemathis study convincingly demonstrated that megestrol acetate can stimulate appetite and food intake in patients with anorexia and cachexia associated with cancer leading to significant weight gain in a proportion of such patients